Summary:
- J.P. Morgan Life Sciences Private Capital appointed Dr. Dashyant Dhanak as Venture Partner.
- Dr. Dhanak brings over 30 years of experience in pharmaceutical research and development.
- J.P. Morgan Life Sciences Private Capital focuses on venture and growth investing in early-stage biotherapeutics and late-stage healthcare companies.
Article:
J.P. Morgan Life Sciences Private Capital Welcomes Dr. Dashyant Dhanak as Venture Partner
J.P. Morgan Life Sciences Private Capital, the venture and growth equity arm of J.P. Morgan Asset Management, recently announced the appointment of Dr. Dashyant Dhanak as their new Venture Partner. With a wealth of experience in pharmaceutical research and development, Dr. Dhanak is set to bring valuable insights and expertise to the firm.
A Seasoned Pharmaceutical Expert
Dr. Dashyant Dhanak boasts an impressive career spanning over 30 years in the pharmaceutical industry. Prior to joining J.P. Morgan Life Sciences Private Capital, he served as the Chief Scientific Officer at Deciphera Pharmaceuticals, where his contributions led to the company’s acquisition by Ono Pharmaceuticals in 2024. Before his time at Deciphera, Dr. Dhanak held the position of Chief Scientific Officer at Incyte, overseeing the research and preclinical development of innovative medicines in hematology, oncology, and immunology.
Focus on Venture and Growth Investing
J.P. Morgan Life Sciences Private Capital is dedicated to supporting early-stage biotherapeutics and late-stage healthcare companies through venture and growth investing. As the life sciences platform of J.P. Morgan Private Capital, the firm plays a crucial role in nurturing innovative solutions and breakthrough technologies in the healthcare sector.
Overall, the appointment of Dr. Dashyant Dhanak as Venture Partner signifies a strategic move for J.P. Morgan Life Sciences Private Capital, strengthening their position in the industry and reinforcing their commitment to supporting groundbreaking advancements in healthcare.
